233 related articles for article (PubMed ID: 12467238)
1. The role of natural killer cells in adenovirus-mediated p53 gene therapy.
Carroll JL; Nielsen LL; Pruett SB; Mathis JM
Mol Cancer Ther; 2001 Nov; 1(1):49-60. PubMed ID: 12467238
[TBL] [Abstract][Full Text] [Related]
2. In vivo studies of adenovirus-based p53 gene therapy for ovarian cancer.
von Gruenigen VE; Santoso JT; Coleman RL; Muller CY; Miller DS; Mathis JM
Gynecol Oncol; 1998 Jun; 69(3):197-204. PubMed ID: 9648587
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of intraperitoneal adenovirus-mediated p53 gene therapy in ovarian cancer.
Von Gruenigen VE; O'Boyle JD; Coleman RL; Wilson D; Miller DS; Mathis JM
Int J Gynecol Cancer; 1999 Sep; 9(5):365-372. PubMed ID: 11240795
[TBL] [Abstract][Full Text] [Related]
4. Recombinant E1-deleted adenovirus-mediated gene therapy for cancer: efficacy studies with p53 tumor suppressor gene and liver histology in tumor xenograft models.
Nielsen LL; Gurnani M; Syed J; Dell J; Hartman B; Cartwright M; Johnson RC
Hum Gene Ther; 1998 Mar; 9(5):681-94. PubMed ID: 9551616
[TBL] [Abstract][Full Text] [Related]
5. The use of laser scanning cytometry to assess depth of penetration of adenovirus p53 gene therapy in human xenograft biopsies.
Grace MJ; Xie L; Musco ML; Cui S; Gurnani M; DiGiacomo R; Chang A; Indelicato S; Syed J; Johnson R; Nielsen LL
Am J Pathol; 1999 Dec; 155(6):1869-78. PubMed ID: 10595917
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models.
Wen SF; Xie L; McDonald M; DiGiacomo R; Chang A; Gurnani M; Shi B; Liu S; Indelicato SR; Hutchins B; Nielsen LL
Cancer Gene Ther; 2000 Nov; 7(11):1469-80. PubMed ID: 11129289
[TBL] [Abstract][Full Text] [Related]
7. Bivariate analysis of the p53 pathway to evaluate Ad-p53 gene therapy efficacy.
Jacobberger JW; Sramkoski RM; Zhang D; Zumstein LA; Doerksen LD; Merritt JA; Wright SA; Shults KE
Cytometry; 1999 Oct; 38(5):201-13. PubMed ID: 10516606
[TBL] [Abstract][Full Text] [Related]
8. NK cells mediate the anti-tumor effects of E1-deleted, type 5 adenovirus in a human tumor xenograft model.
Nielsen LL
Oncol Rep; 2000; 7(1):151-5. PubMed ID: 10601610
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo adenovirus-mediated p53 and p16 tumor suppressor therapy in ovarian cancer.
Modesitt SC; Ramirez P; Zu Z; Bodurka-Bevers D; Gershenson D; Wolf JK
Clin Cancer Res; 2001 Jun; 7(6):1765-72. PubMed ID: 11410518
[TBL] [Abstract][Full Text] [Related]
10. Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer.
Gurnani M; Lipari P; Dell J; Shi B; Nielsen LL
Cancer Chemother Pharmacol; 1999; 44(2):143-51. PubMed ID: 10412949
[TBL] [Abstract][Full Text] [Related]
11. The effect of the Cmv-1 resistance gene, which is linked to the natural killer cell gene complex, is mediated by natural killer cells.
Scalzo AA; Fitzgerald NA; Wallace CR; Gibbons AE; Smart YC; Burton RC; Shellam GR
J Immunol; 1992 Jul; 149(2):581-9. PubMed ID: 1378069
[TBL] [Abstract][Full Text] [Related]
12. [Gene therapy for ovarian cancers by adenovirus-mediated complete antibody gene].
Guo MG; Jiang MH; Yang Q; Li YM; Cui ZF; Li LF; Wu MC; Qian QJ
Zhonghua Yi Xue Za Zhi; 2004 Jul; 84(14):1147-51. PubMed ID: 15387973
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity.
Slos P; De Meyer M; Leroy P; Rousseau C; Acres B
Cancer Gene Ther; 2001 May; 8(5):321-32. PubMed ID: 11477452
[TBL] [Abstract][Full Text] [Related]
14. Natural killer cell activation primes macrophages to clear bacterial infection.
Scott MJ; Hoth JJ; Gardner SA; Peyton JC; Cheadle WG
Am Surg; 2003 Aug; 69(8):679-86; discussion 686-7. PubMed ID: 12953826
[TBL] [Abstract][Full Text] [Related]
15. In vivo studies of adenovirus-mediated p53 gene therapy for cis-platinum-resistant human ovarian tumor xenografts.
Song K; Cowan KH; Sinha BK
Oncol Res; 1999; 11(3):153-9. PubMed ID: 10527075
[TBL] [Abstract][Full Text] [Related]
16. Adenovirus-based p53 gene therapy in ovarian cancer.
Santoso JT; Tang DC; Lane SB; Hung J; Reed DJ; Muller CY; Carbone DP; Lucci JA; Miller DS; Mathis JM
Gynecol Oncol; 1995 Nov; 59(2):171-8. PubMed ID: 7590467
[TBL] [Abstract][Full Text] [Related]
17. Intraperitoneal delivery of human natural killer cells for treatment of ovarian cancer in a mouse xenograft model.
Geller MA; Knorr DA; Hermanson DA; Pribyl L; Bendzick L; McCullar V; Miller JS; Kaufman DS
Cytotherapy; 2013 Oct; 15(10):1297-306. PubMed ID: 23993303
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon.
Akbulut H; Zhang L; Tang Y; Deisseroth A
Cancer Gene Ther; 2003 May; 10(5):388-95. PubMed ID: 12719708
[TBL] [Abstract][Full Text] [Related]
19. Adenovirus-mediated calponin h1 gene therapy directed against peritoneal dissemination of ovarian cancer: bifunctional therapeutic effects on peritoneal cell layer and cancer cells.
Ogura T; Kobayashi H; Ueoka Y; Okugawa K; Kato K; Hirakawa T; Hashimoto S; Taniguchi S; Wake N; Nakano H
Clin Cancer Res; 2006 Sep; 12(17):5216-23. PubMed ID: 16951241
[TBL] [Abstract][Full Text] [Related]
20. Renal cell carcinoma and natural killer cells: studies in a novel rat model in vitro and in vivo.
Winter BK; Wu S; Nelson AC; Pollack SB
Cancer Res; 1992 Nov; 52(22):6279-86. PubMed ID: 1423274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
